This article reviews recent advances in imaging and fluid biomarkers for Alzheimer disease (AD) and their application to newly proposed diagnostic criteria across the continuum of AD.
& The cholinergic hypothesis of memory impairment implies that cholinergic deficits are responsible for cognitive and behavioral changes in patients with dementia and age-related memory impairment, and that augmentation of central cholinergic function will improve cognitive function. & Historically, the targeted cholinergic treatment approaches have included using (1) acetylcholine precursors;
(2) direct cholinergic agonists; and (3) cholinesterase inhibitors. & The most common adverse events due to cholinesterase inhibitors include nausea, diarrhea, vomiting, anorexia, and weight loss. Muscle cramps are common with donepezil. & Early cholinergic effects are frequently related to the initial dosing and titration of the medications. & Anorexia varies in incidence from 8% to 25% at higher doses of cholinesterase inhibitors compared with 3% to 10% in patients on placebo and may be dose related. The proportion of patients with weight loss in clinical trials ranges from 10% to 24% in patients taking higher doses compared to 2% to 10% of placebo-treated patients. & An analysis of Canadian medical and prescription records showed that patients on cholinesterase inhibitors were hospitalized for syncope nearly twice as often as people with dementia who did not receive these drugs. & Despite differences in mechanism of action and dosing levels, no evidence exists for efficacy differences between the three cholinesterase inhibitors. In a Cochrane review, the drugs are associated with an overall mean 2.4 points effect over placebo on the Alzheimer Disease Assessment ScaleVCognitive Subscale. & A 23-mg extended release formulation of donepezil is intended to be used after a patient has been treated with 10 mg/d for at least 3 months and when the clinician is uncertain whether the patient is benefiting from the 10-mg dose. & Cholinesterase inhibitors are not indicated for mild cognitive impairment, yet their use may be common practice. Clinical trials of cholinesterase inhibitors in MCI were not positive on their primary outcomes and showed an excess in adverse events. & Memantine was approved by the US Food and Drug Administration in late 2003 for moderate to severe Alzheimer disease. The basis for approval was positive outcomes on two 6-month-long placebo-controlled clinical trials. In one trial cholinesterase inhibitors were not allowed, and in another, patients had been taking donepezil for at least 6 months (over 2 years on average). A third trial did not show significant effects. & Only one of three trials of memantine in mild to moderate Alzheimer disease showed significant improvement on the Alzheimer Disease Assessment ScaleVCognitive Subscale and global assessment. Memantine has not been approved by the US Food and Drug Administration for patients with mild Alzheimer disease. & A Cochrane review concluded that memantine had a small beneficial effect in moderate to severe Alzheimer disease and was well tolerated. & Adverse events with memantine are infrequent but can include headache, dizziness, confusion, somnolence, and infrequent hallucinations. In clinical trials, the frequency of gastrointestinal symptoms is less than placebo; diarrhea occurred half as often. & Extracts from leaves of the Ginkgo biloba, or maidenhair, tree are widely sold in the United States as food supplements for which health claims are not permitted. A specific standardized extract, EGb 761, is approved by the formularies of Germany and France. & G biloba extract is also used as a memory enhancer in people without Alzheimer disease; however, clinical trials in older and younger adults who do not have cognitive impairment show mixed results at best. & A Cochrane review that included 35 clinical trials reported inconsistent evidence that G biloba had clinically significant benefits for dementia or cognitive impairment. & A medical food is a food formulated for the dietary management of an illness that has distinctive nutritional requirements, and is intended to be used under medical supervision. & A formulation of medium-chain triglycerides is marketed as a medical food for Alzheimer disease in the United States. Another medical food, marketed in late 2012 in Europe and Brazil, is a combination of compounds including uridine, choline, omega-3 fatty acids, phospholipids, B vitamins, and antioxidants, intended to enhance synaptic function and neurotransmitters, presumably improving cognitive function. Controlled trials of these two medical foods have not been positive. & It is difficult to identify the individual patient who benefits from cholinesterase inhibitors or memantine because the outcome measures and mean changes on scale scores do not identify responders. & Discontinuation of cholinesterase inhibitors has been associated with worsening of cognition and confusion in some patients in trials. Yet worsening of behavior and confusion do not appear common when the drugs are stopped in clinical practice. In clinical practice, 19% to 23% of patients continued to take donepezil or rivastigmine for more than 1 year, and about one-third discontinued the drugs within 2 months. & In a withdrawal trial after maintenance treatment with donepezil for 2 to 3 years in severely impaired patients with Alzheimer disease, continuing donepezil was associated with better cognitive scores and activities of daily living. Many patients discontinued donepezil without difficulty, and only half of the patients assigned to continue donepezil actually continued treatment beyond the 1-year follow-up. Thus, the outcomes support decisions either to continue medication or to taper and discontinue it when physicians are uncertain of continuing benefit. & Only three of 14 trials showed significant effects for cholinesterase inhibitors improving behavior; none of these effects was large. Trivial effects were reported in the more mildly cognitively impaired patients, but no effect was reported in the more severely impaired. & Regulatory criteria for marketing symptomatic and disease-modifying therapies require demonstrating improvements in cognition and activities of daily living, overall improvements compared to placebo, and adequate safety. & The gist of the amyloid cascade hypothesis is that amyloid-A deposition drives tau phosphorylation, tangle formation, and neuron death.
& There are several amyloid-AYtargeted experimental approaches, including modulation of amyloid-A production, inhibition of amyloid-A aggregation, enhancement of amyloid-A degradation, and use of passive and active immunization to raise antibodies that target and remove amyloid-A. & The range of anti-tau therapeutic approaches under development include inhibiting tau kinases; enhancing phosphatase activity in an effort to enhance microtubule stability; blocking or inhibiting tau hyperphosphorylation, tau aggregates, and filament formation; and enhancing clearance of aggregates with drugs or antibodies. & Challenges to developing effective treatments for Alzheimer disease include the uncertainty and lack of validated drug and molecular targets and the ability to conduct efficient clinical development programs. Establishing validated drug targets requires greater understanding of the pathogenic processes leading to illness.
The genetic architecture of AD is complex, as it includes multiple susceptibility genes and likely nongenetic factors. Rare but highly penetrant autosomal dominant mutations explain a small minority of the cases but have allowed tremendous advances in understanding disease pathogenesis. The identification of a strong genetic risk factor, APOE, reshaped the field and introduced the notion of genetic risk for AD. More recently, large-scale genome-wide association studies are adding to the picture a number of common variants with very small effect sizes. Large-scale resequencing studies are expected to identify additional risk factors, including rare susceptibility variants and structural variation.
Summary:
Genetic assessment is currently of limited utility in clinical practice because of the low frequency (Mendelian mutations) or small effect size (common risk factors) of the currently known susceptibility genes. However, genetic studies are identifying with confidence a number of novel risk genes, and this will further our understanding of disease biology and possibly the identification of therapeutic targets.
& Although cases of Alzheimer disease inherited in a Mendelian fashion are rare (accounting for approximately 1% of cases), genetic factors are likely to play an important role in all forms of the disease. & Studying large populations with sensitive techniques has allowed the identification of several new genes consistently associated with Alzheimer disease risk. However, the overall magnitude of the risk conferred by each of these is small, and therefore the clinical relevance of these findings is as yet undefined. Nonetheless, study of the pathways through which these genes contribute to Alzheimer disease pathology is an avenue toward the identification of potential therapeutic targets. & Although substantive disease-modifying interventions do not yet exist, these advances have enabled definitive diagnosis of familial Alzheimer disease and therefore can have significant effects on patients and their families in terms of understanding the illness, its inheritance, and its prognosis. Furthermore, this progress allows for the possibility of presymptomatic testing in unaffected at-risk subjects. Therefore, clinicians should have a thorough understanding of the phenotypes and of testing that is available. & The existence of these groups of familialYAlzheimer disease families of specific ethnic and geographic origins indicates that inquiring about patients' ancestral origins can be informative. & In a retrospective chart review comparing clinical features between 32 patients with familial Alzheimer disease due to PSEN1 mutations and 81 patients with nonfamilial early-onset Alzheimer disease, those with PSEN1 mutations tended to be younger (42 versus 56 years of age at onset), more likely to have memory complaints as the presenting feature (84% versus 58%, with nonfamilial cases frequently presenting with visuospatial and language deficits) and more likely to experience significant headaches, myoclonus, gait abnormalities, and pseudobulbar affect. The presence of such features in a young-onset case of Alzheimer disease when the family history is unavailable should prompt the clinician to consider genetic testing. & Because the pathogenicity of identified variants in PSEN2 (and other familial Alzheimer disease genes) is not always clear, caution needs to be exercised when interpreting results of genetic testing with patients and their families. & Trials to prevent familial Alzheimer disease by administering experimental medications to asymptomatic mutation carriers are in development and should commence in 2013. & In humans, APOE is highly polymorphic; the APOE*E3 allele is the most common, followed by the *E4 allele, which is in turn more common than the *E2 allele. The *E3, *E4, and *E2 alleles, which differ in only one or two amino acids, have been reproducibly shown to have differential effects on risk of late-onset Alzheimer disease, with *E4 conferring a greater risk than *E3, which in turn confers a higher risk than the *E2 allele, with odds ratios between approximately 4 for heterozygous and approximately 15 for homozygous carriers of the *E4 allele. & There is ample convergent evidence for ApoE as a potential therapeutic target for disease-modifying interventions in Alzheimer disease. & The prevalence of the *E4 allele in the population varies depending on ethnicity but is typically in the range of 15% to 20%. Among people with Alzheimer disease, the prevalence is around 50%, again depending on the specific population being studied. The increased risk conferred by the *E4 allele is generally thought to be a three-to fourfold 
The Clinical Problem of Neuropsychiatric Signs and Symptoms in Dementia
Recent Findings:
Almost all patients with a dementia will develop significant behavioral disturbances at some point over the course of their illness. These behavioral signs and symptoms rarely fit into usual diagnostic classifications or meet full criteria for a formal major psychiatric disorder.
Summary:
Treatment of behavioral signs and symptoms of dementia should include both pharmacologic and nonpharmacologic interventions. There are currently no treatments for these disturbances approved by the US Food and Drug Administration. Best judgment should be used in identifying dominant target symptoms and matching them to the most relevant drug class. Implementing nonpharmacologic interventions before the development of neuropsychiatric symptoms may prevent triggers related to a progressively lowered stress threshold and therefore is key in the treatment of all patients with a dementia. Alzheimer disease pathology is present, they do not provide information about when the patient will progress to an Alzheimer disease clinical dementia. & There are no therapies that can prevent the conversion from mild cognitive impairment to Alzheimer disease. However, studies conducted with cholinesterase inhibitors have shown a modest cognitive improvement in subjects with mild cognitive impairment treated with these medications compared to placebo.
Key Points
relates to other disease processes (eg, co-occurrence with Alzheimer disease). A recent American Heart Association and American Stroke Association guidance statement clarified the construct of VCI, including the severity of cognitive and behavioral dysfunction contained under the definition of VCI and the presence of both ''pure'' and ''mixed'' VCI forms. VCI treatments approved by the US Food and Drug Administration are still lacking, and challenges remain regarding how to convert promising observational study findings that link stroke and coronary heart disease risk factors to cognitive impairment and dementia into evidence-based preventive methods.
Summary:
VCI is a common contributor to cognitive impairment in later life. Because the risk of Alzheimer disease may be heightened by the same risk factors that make us susceptible to stroke and coronary heart disease, these borderlands merit careful consideration as we strive to preserve cognitive function throughout the aging process.
Key Points
& Vascular cognitive impairment is defined as ''a syndrome with evidence of clinical stroke or subclinical vascular brain injury and cognitive impairment affecting at least one cognitive domain.'' Vascular cognitive impairment therefore encompasses all of the potential levels of cognitive severity, from its mildest form detectable by neuropsychological assessment to full-blown vascular dementia. & Strokes and Alzheimer disease often occur concomitantly and pose risks for one another. & Vascular dementia has been considered the second leading cause of progressive and irreversible dementia after Alzheimer disease. & Neuropathologic studies show an additive influence or correlation between Alzheimer disease pathology and cerebral infarction in the manifestation of cognitive impairment. & Traditionally, survival in Alzheimer disease is longer than in vascular dementia or mixed dementia, but survival varies according to the patient's age, race or ethnic group, and severity of cognitive impairment. & Lowering blood pressure in patients who do not have cognitive impairment can reduce the risk of subsequent cognitive impairment, whereas lowering blood pressure to preserve cognition among patients who already have cognitive impairment remains unproven as a successful strategy. & Risks for stroke, such as hypertension, hypercholesterolemia, hyperhomocysteinemia, elevated body mass index and fat intake, atrial fibrillation, diabetes mellitus, cigarette smoking, and metabolic syndrome, are now considered risks not only for vascular cognitive impairment but also for Alzheimer disease. & In addition to clinically manifest strokes, vascular cognitive impairment may have an underpinning of subclinical cerebrovascular brain injury. & At the microscopic level of the brain, the neurovascular unit is a conduit for neurovascular dysfunction. & The most common form of vascular cognitive impairment is the subcortical type. & Regional white matter integrity (whether on the side of a recent acute cerebrovascular brain injury or not) and thalamic density have been suggested as possible pathogenetic links for risk of vascular cognitive impairment based on diffusion tensor imaging and voxel-based morphometry study, respectively. & The clinical picture of patients with vascular cognitive impairment may be linked with the volume and location of the underlying pathology.
& Individual patients may show both focal neurocognitive deficits associated with the location of their stroke lesions and a more diffuse pattern, depending on the presence and extent of subcortical cerebrovascular brain injury. & Given the lack of clarity from research studies and the fact that many elderly patients with dementia and cognitive impairment have multiple sources of brain pathology, clinicians should be cautious about basing their clinical diagnosis solely on the pattern of cognitive deficits. & The pattern of memory impairment in vascular cognitive impairment can be qualitatively different from that of Alzheimer disease. & It is important to screen for depressive symptoms in patients with suspected cerebrovascular brain injury. & Reliably differentiating functional disability due to physical (eg, hemiparesis) versus cognitive and behavioral impairment is a specific difficulty in examining for impaired activities of daily living after stroke. & There is reasonable evidence to suggest blood pressureYlowering therapy as a useful intervention for people who are middle-aged and younger elderly (Class IIa, Level of Evidence B); however, the usefulness of lowering blood pressure for those over 80 years of age for the prevention of dementia is not well established (Class IIb, Level of Evidence B). & Further robust and consistent studies are necessary to provide clear, concise answers to important research questions regarding the role of vascular risks for cognitive impairment and dementia. & Currently no drugs that have gained wide acceptance for use in practice have been approved by the US Food and Drug Administration for the treatment of vascular cognitive impairment. & The failure of the cholinesterase inhibitors to successfully treat patients with vascular dementia on an across-the-board cognitive and functional basis has raised questions regarding whether there is an absence of cholinergic deficits in pure vascular dementia.
after Alzheimer disease. Neurologists, neuropsychologists, and speech pathologists are particularly involved in the diagnosis and recognition of etiologies for patients with deficits in frontal lobe function and language.
The recent discovery of a novel mutant gene (C9ORF72) and the new nomenclature adopted for subclassification have significantly promoted our understanding of this disorder.
Summary:
This article relates the most recent consensus criteria for diagnosis of the two forms of frontotemporal degeneration (ie, behavioral and primary progressive aphasia variants) to basic neurologic principles and remind clinicians of the neuropsychiatric and neuroradiologic components that clarify frontotemporal degeneration diagnoses and guide management.
Key Points
& Diagnostic criteria now allow for a subclass of possible behavioral variant frontotemporal degeneration, which represents earlier stages of illness in which neuropsychological testing in high-functioning patients may not reveal executive deficits or in which neuroimaging does not yet support regional atrophy or regional dysfunction. & Consultation with speech and language pathologists (especially in mildly affected cases)
is invaluable, as some of the features of the primary progressive aphasias are difficult to identify without subspecialty training. & Unlike probable behavioral variant frontotemporal degeneration, activities of daily living are maintained well into illness, except those related to language (eg, using the telephone & Not all patients with family histories of similar symptoms, Parkinson disease, ALS, or primary psychiatric disorder have positive genetic testing. & Positive family histories are most commonly elicited from patients with behavioral variant frontotemporal degeneration and frontotemporal degeneration with ALS and infrequently from patients with semantic dementia. & The most common clinical phenotype associated with both MAPT and GRN mutations is behavioral variant frontotemporal degeneration, although a more varied clinical spectrum has been associated with GRN mutations, including diagnoses such as primary progressive aphasia and corticobasal syndrome. & A major recent discovery identified C9ORF72, which appears to be the most common genetic abnormality both in familial behavioral variant frontotemporal degeneration (11.7% of cases) and ALS (23.5%). & There is no CSF biomarker specific for the diagnosis of frontotemporal degeneration. & The clinical trial yielding the highest level of evidence (through a randomized, double-blind, placebo-controlled crossover trial) in frontotemporal degeneration used trazodone at a dose of 100mg orally three times a day. & One challenge for the clinician is to determine whether the behavioral and psychiatric symptoms of dementia are a manifestation along the anxiety spectrum (including obsessive-compulsive features) or represent agitation. & Acetylcholinesterase inhibitors developed to improve symptoms of Alzheimer disease do not seem to be effective in managing symptoms of frontotemporal degeneration, perhaps because the cholinergic neurons in the nucleus basalis of Meynert are relatively spared in frontotemporal degeneration. & Regardless of the medication prescribed, it behooves the clinician to make sure that the caregiver understands the symptoms targeted by the medication so that there can be an ongoing dialogue about whether the medication is working or is still indicated. & One of the most influential changes in behavioral management has been the shift away from medical models of treatment for behavioral and psychiatric symptoms of dementia toward the reconceptualization of behavioral and psychiatric symptoms of dementia as responsive behaviors. & Because patients with early-onset dementia may have children with a wide range of ages who are active informal caregivers, there is a need for groups that support children and emphasize balance between growing up and caregiving.
